双硫死亡与其他细胞死亡在卵巢癌治疗中的研究进展

doi:10.20223/j.cnki.1000-8535.2025.04.004

摘要/Abstract

摘要： 卵巢癌是导致女性死亡的全球第五大原因,其治疗效果受限于早期诊断和治疗方案的有限性。近年来,随着靶向治疗的不断发展,细胞死亡途径作为治疗靶点受到广泛关注,其中双硫死亡作为一种新发现的程序性细胞死亡形式,为癌症治疗提供了新的思路。文章探讨了双硫死亡及其他主要细胞死亡途径包括自噬、细胞焦亡、坏死性凋亡、铁死亡和铜死亡在卵巢癌治疗中的研究进展,有望为卵巢癌患者提供更有效的治疗选择。

关键词: 卵巢癌, 双硫死亡, 细胞死亡, 癌症治疗

Abstract: Ovarian cancer ranks as the fifth deadliest cancer among women worldwide,with treatment efficacy hampered by limited early diagnosis and therapeutic options．In recent years,with the continuous development of targeted therapies,cell death pathways have gained widespread attention as therapeutic targets．Among them,disulfideptosis,a newly discovered form of programmed cell death,offers a novel avenue for cancer treatment．This review aims to explore the research progress of disulfideptosis and other major cell death pathways including autophagy,apoptosis,necroptosis,ferroptosis,and cuproptosis in ovarian cancer therapy,with the potential to provide more effective treatment options for ovarian cancer patients．

Key words: ovarian cancer, disulfideptosis, cell death, cancer therapy

杨佳林, 谢晓英. 双硫死亡与其他细胞死亡在卵巢癌治疗中的研究进展[J]. 广州医药, 2025, 56(4): 452-456.

YANG Jialin, XIE Xiaoying. Research progress on disulfideptosis and other cell death pathways in ovarian cancer treatment[J]. Guangzhou Medical Journal, 2025, 56(4): 452-456.

参考文献

[1] PAL S,BHOWMICK S,SHARMA A,et al.Lymphatic vasculature in ovarian cancer[J].Biochim Biophys Acta Rev Cancer,2023,1878(5):188950.
[2] CHAN JK,TIAN C,KESTERSON J P,et al.Symptoms of women with high-risk early-stage ovarian cancer[J].Obstet Gynecol,2022,139(2):157-162.
[3] 张珩,郑慧,卢仁泉.卵巢癌微环境调控调节性T细胞的研究进展[J].检验医学,2024,39(4):317-323.
[4] AKTER S,RAHMAN M A,HASAN M N,et al.Recent advances in ovarian cancer:Therapeutic strategies,potential biomarkers,and technological improvements[J].Cells,2022,11(4):650.
[5] OGASAWARA A,SATO S,HASEGAWA K.Current and future strategies for treatment of ovarian clear cell carcinoma[J].J Obstet Gynaecol Res,2020,46(9):1678-1689.
[6] KONSTANTINOPOULOS P A,MATULONIS U A.Clinical and translational advances in ovarian cancer therapy[J].Nat Cancer,2023,4(9):1239-1257.
[7] GONG L,HUANG D,SHI Y,et al.Regulated cell death in cancer:From pathogenesis to treatment[J].Chin Med J(Engl),2023,136(6):653-665.
[8] TONG X,TANG R,XIAO M,et al.Targeting cell death pathways for cancer therapy:Recent developments in necroptosis,pyroptosis,ferroptosis,and cuproptosis research[J].J Hematol Oncol,2022,15(1):174.
[9] 徐豪,禹娜.调节性细胞死亡机制概述[J].生物学教学,2024,49(2):2-7.
[10] ZHENG T,LIU Q,XING F,et al.Disulfidptosis:A new form of programmed cell death[J].J Exp Clin Cancer Res,2023,42(1):137.
[11] 赵琪琪,杜雪芹,刘松华,等.SLC7A11表达与双硫死亡、铁死亡及肿瘤关系的研究进展[J].江苏大学学报(医学版),2023,33(5):398-403.
[12] JIN M,NI D,CAI J,et al.Identification and validation of immunity- and disulfidptosis-related genes signature for predicting prognosis in ovarian cancer[J].Heliyon,2024,10(12):e32273.
[13] ZENG Q,MA X,SONG Y,et al.Targeting regulated cell death in tumor nanomedicines[J].Theranostics,2022,12(2):817-841.
[14] TUMMERS B,GREEN D R.The evolution of regulated cell death pathways in animals and their evasion by pathogens[J].Physiol Rev,2022,102(1):411-454.
[15] D’ARCY M S.Cell death:A review of the major forms of apoptosis,necrosis and autophagy[J].Cell Biol Int,2019,43(6):582-592.
[16] CHRISTGEN S,TWEEDELL R E,KANNEGANTI T D.Programming inflammatory cell death for therapy[J].Pharmacol Ther,2022(232):108010.
[17] LIU X,NIE L,ZHANG Y,et al.Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis[J].Nat Cell Biol,2023,25(3):404-414.
[18] ZHENG P,ZHOU C,DING Y,et al.Disulfidptosis:A new target for metabolic cancer therapy[J].J Exp Clin Cancer Res,2023,42(1):103.
[19] CONG Y,CAI G,DING C,et al.Disulfidptosis-related signature elucidates the prognostic,immunologic,and therapeutic characteristics in ovarian cancer[J].Front Genet,2024(15):1378907.
[20] FANTONE S,PIANI F,OLIVIERI F,et al.Role of SLC7A11/xCT in ovarian cancer[J].Int J Mol Sci,2024,25(1):587.
[21] JUNG S,JEONG H,YU SW.Autophagy as a decisive process for cell death[J].Exp Mol Med,2020,52(6):921-930.
[22] PARK M,CHOE S,SHIN M,et al.Potential therapeutic targets in ovarian cancer:Autophagy and metabolism[J].Front Biosci(Landmark Ed),2023,28(3):47.
[23] 杨璇,张玉洲,郭靖.自噬抑制剂促进紫杉醇耐药卵巢癌细胞对化疗敏感性的研究[J].实用癌症杂志,2024,39(2):181-185.
[24] CHEN J,WEI Z,FU K,et al.Non-apoptotic cell death in ovarian cancer:Treatment,resistance and prognosis[J].Biomed Pharmacother,2022(150):112929.
[25] VANDENABEELE P,BULTYNCK G,SAVVIDES S N.Pore-forming proteins as drivers of membrane permeabilization in cell death pathways[J].Nat Rev Mol Cell Biol,2023,24(5):312-333.
[26] WANG A,WANG Y,DU C,et al.Pyroptosis and the tumor immune microenvironment:A new battlefield in ovarian cancer treatment[J].Biochim Biophys Acta Rev Cance, 1879(2):189058.
[27] 郭红磊,王爱迪,刘宝山.基于细胞焦亡理论探讨“炎-癌转化”与中医药防治肿瘤思路[J].中医药信息,2023,40(5):45-50.
[28] ROBERTS J Z,CRAWFORD N,LONGLEY D B.The role of Ubiquitination in Apoptosis and Necroptosis[J].Cell Death Differ,2022,29(2):272-284.
[29] ZHU X,LI S.Ferroptosis,necroptosis,and pyroptosis in gastrointestinal cancers:The chief culprits of tumor progression and drug resistance[J].Adv Sci(Weinh),2023,10(26):e2300824.
[30] WANG B,CUI Y,ZHANG Q,et al.Selenomethionine alleviates LPS-induced JNK/NLRP3 inflammasome-dependent necroptosis by modulating miR-15a and oxidative stress in chicken lungs[J].Metallomics,2021,13(8):mfab048.
[31] ZHANG C,LIU N.Ferroptosis,necroptosis,and pyroptosis in the occurrence and development of ovarian cancer[J].Front Immunol,2022(13):920059.
[32] VERDONCK S,NEMEGEER J,VANDENABEELE P,et al.Viral manipulation of host cell necroptosis and pyroptosis[J].Trends Microbiol,2022,30(6):593-605.
[33] HAHNE JC,KURZ A,MEYER S R,et al.Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer[J].Arch Gynecol Obstet,2015,291(1):131-141.
[34] 罗永金,胡晓霞,林泳秀.基于生物信息学筛选卵巢癌预后的坏死性凋亡相关基因[J].广西医学,2023,45(21):2629-2636.
[35] 王自有,王锐,赵耀伟,等.铁死亡机制在食管癌预后中的作用研究进展[J].现代医院,2023,23(11):1797-1800,1804.
[36] XU L,LIU Y E,CHEN X,et al.Ferroptosis in life:To be or not to be[J].Biomed Pharmacother,2023(159):114241.
[37] 殷美芸,孙文霞.铁死亡的调控机制及在女性生殖系统疾病中的研究进展[J].齐齐哈尔医学院学报,2023,44(14):1357-1362.
[38] XUAN Y,WANG H,YUNG M M,et al.SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells[J].Theranostics,2022,12(7):3534-3552.
[39] LANG X,GREEN MD,WANG W,et al.Radiotherapy and immunotherapy promote tumoral Lipid oxidation and ferroptosis via synergistic repression of SLC7A11[J].Cancer Discov,2019,9(12):1673-1685.
[40] WANG W,GREEN M,CHOI J E,et al.CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy[J].Nature,2019,569(7755):270-274.
[41] ZHAO H,XU Y,SHANG H.Ferroptosis:A new promising target for ovarian cancer therapy[J].Int J Med Sci,2022,19(13):1847-1855.
[42] WANG M,ZHENG L,MA S,et al.Cuproptosis:Emerging biomarkers and potential therapeutics in cancers[J].Front Oncol,2023(13):1288504.
[43] 张萌,石萌,刘宝琴.铜稳态失衡相关疾病及铜死亡的研究进展[J].中国医科大学学报,2023,52(12):1125-1130.
[44] de LUCA A,BARILE A,ARCIELLO M,et al.Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy[J].J Trace Elem Med Biol,2019(55):204-213.
[45] GUO J,SUN Y,LIU G.The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis[J].J Inorg Biochem,2023(247):112324.
[46] XIE J,YANG Y,GAO Y,et al.Cuproptosis:Mechanisms and links with cancers[J].Mol Cancer,2023,22(1):46.